Document Detail


Lipid metabolism in cystic fibrosis.
MedLine Citation:
PMID:  19209467     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: Expression of defective cystic fibrosis transmembrane conductance regulator (CFTR), the cause for cystic fibrosis, affects fatty acid, cholesterol and sphingolipid metabolism. This review summarizes recent observations and evaluates current understanding of mechanisms. RECENT FINDINGS: Recent observations implicate CFTR, in addition to known effects on fatty acid and cholesterol metabolism, in the regulation of sphingolipid metabolism and suggest that this pathway is relevant to inflammation and infection. A common mechanism on how CFTR affects such a wide spectrum of lipid classes is currently not known. One mechanism for low linoleic acid, amenable to inhibition by docosahexaenoic acid, is increased metabolism in the n-6 fatty acid pathway. Accumulation of free cholesterol in distinct perinuclear compartments, reversible by overexpression of rab9, suggests that cystic fibrosis and the lysosomal storage disease Niemann-Pick-C could share similar cell signaling defects, in addition to increased cAMP signaling and sterol-regulatory element binding protein (SREBP) expression that affect cholesterol metabolism. Novel is the recognition that CFTR modulates ceramide mass and uptake of sphingosine-1- phosphate. Experiments in different cystic fibrosis-mouse models, although not able to establish whether ceramide mass is increased or decreased, suggest that normalization of ceramide decreases infection and selected parameters of inflammation, of relevance to the complex phenotype that characterizes cystic fibrosis. SUMMARY: Expression of defective CFTR has profound effects on fatty acid, cholesterol and sphingolipid metabolism, for which mechanisms are currently poorly understood. Recent studies in different cystic fibrosis models suggest a causal relationship between altered ceramide mass and increased inflammation and susceptibility to infection. Studies in cystic fibrosis knockout mouse models suggest that normalization of ceramide decreases infection and inflammation. Studies that evaluate the diagnostic and clinical relevance of sphingolipids in patients with cystic fibrosis are needed.
Authors:
Tilla S Worgall
Related Documents :
6338497 - Sterol synergism in yeast.
16131527 - Human liver cholesteryl ester hydrolase: cloning, molecular characterization, and role ...
10428977 - Elimination of cholesterol as cholestenoic acid in human lung by sterol 27-hydroxylase:...
6512417 - Characterization of human liver 3-o-beta-d-glucopyranuronosyl-cholesterol by mass spect...
9638867 - Effect of isoleucine on toxin production by clostridium difficile in a defined medium.
8660537 - Identification of monohydroxy fatty acids by electrospray mass spectrometry and tandem ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current opinion in clinical nutrition and metabolic care     Volume:  12     ISSN:  1535-3885     ISO Abbreviation:  Curr Opin Clin Nutr Metab Care     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-02-11     Completed Date:  2009-04-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9804399     Medline TA:  Curr Opin Clin Nutr Metab Care     Country:  England    
Other Details:
Languages:  eng     Pagination:  105-9     Citation Subset:  IM    
Affiliation:
Department of Pathology, Pediatrics and Institute of Human Nutrition, Columbia University, BB 457, New York 10032, USA. tpw7@columbia.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Ceramides / metabolism
Cholesterol / metabolism
Cystic Fibrosis / metabolism*
Cystic Fibrosis Transmembrane Conductance Regulator / metabolism*
Dietary Supplements
Fatty Acids / administration & dosage,  metabolism
Humans
Lipid Metabolism*
Sphingolipids / metabolism
Grant Support
ID/Acronym/Agency:
KO8 AG025833/AG/NIA NIH HHS
Chemical
Reg. No./Substance:
0/Ceramides; 0/Fatty Acids; 0/Sphingolipids; 126880-72-6/Cystic Fibrosis Transmembrane Conductance Regulator; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biphenotypic and bilineal acute leukemias
Next Document:  Phytosterols as functional food ingredients: linkages to cardiovascular disease and cancer.